Genprex Announces Clinical Program Update On GPX-002 Diabetes Gene Therapy Candidate

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies

AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mouse and non-human primate (NHP) models, specifically addressing Type 2 diabetes (T2D).